Microbot Medical (MBOT)

Executive Summary

Microbot Medical is a publicly traded company developing the world's first single-use endovascular robotic system, designed to democratize access to minimally invasive robotic surgery. The company's technology aims to address key barriers in current robotic platforms, including high cost, large footprint, and complexity, by offering a compact, disposable, and affordable solution. Microbot Medical is currently in the pre-commercial stage, with no disclosed pipeline products or FDA approvals, but its innovative approach has the potential to disrupt the endovascular robotics market, estimated to grow significantly over the next decade. The company trades under ticker MBOT and has a market capitalization of approximately $144 million. While still early-stage, Microbot Medical represents a high-risk, high-reward opportunity for investors focused on emerging medical robotics.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance for the LIBERTY Robotic System50% success
• TBDStrategic Partnership or Licensing Deal40% success
• TBDClinical Trial Results or First-in-Human Study35% success